Merck & Co Inc said on Friday it expects sales growth in the range of 5 to 6 percent for its corneal stem cell unit, EyeColor, over the course of 2020 as shipments of its infant products have improved in the theater, after an initial 9.8 percent contraction during the COVID-19 pandemic.
Merck said it expects sales to grow into 2.6 to 3.2 percent of 2020, with the non-surgical unit, which includes certain prescription eyeglasses and capillaries, growing into 7 percent.
Merck’s EyeColor unit, the second-largest unit, has posted adjusted sales growth in the range of 4 to 7 percent.
Merck’s neurobiology unit, which includes cornea and laboratory equipment, sold 4.6 million units to U.S.
consumers on end of last year, following an 8.7 percent increase in the comparable period.
Merck CEO Frazier Says Improved Awards Function During COVID-19 Pandemic
